Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552886 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT04552886: Completed Phase 1 study of Glioblastoma, sponsored by The Cooper Health System.
NCT04552886 is a Phase 1 study of Glioblastoma that has completed, run by The Cooper Health System. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552886, a Phase 1 study of Glioblastoma, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient progression-free survival and overall survival.
Primary Outcome
Patients will be monitored for adverse events as dictated by CTCAE version 5.
Conditions Studied
Interventions
- BIOLOGICAL TH-1 Dendritic Cell Immunotherapy
Study Locations (2)
New Jersey
- Cooper University Hospital - Camden
Texas
- Memorial Hermann- Texas Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
What the finished NCT04552886 record still lists
NCT04552886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which TH-1 Dendritic Cell Immunotherapy is the first listed.
NCT04552886 reports a single indexed study location in New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT04552886 about?
NCT04552886 is a clinical study titled "Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma". Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient prog...
What is the current status of trial NCT04552886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-10-11. Estimated completion is 2023-12-01.
What conditions does trial NCT04552886 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04552886?
The interventions under investigation include: TH-1 Dendritic Cell Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04552886?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04552886 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04552886's enrollment target sits among peer trials
17 166th of 199 higher than 31 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI